News

Over $4.7 Million Raised at Gala for Diabetes Research Support

Over $4.7 Million Raised at Gala for Diabetes Research Support

Fundraising Success at Connect+Cure Gala

More than 800 attendees participated in an impressive fundraising event, the Connect+Cure Gala, which successfully raised $4.7 million to enhance research and various programs at the University of Oklahoma Health Harold Hamm Diabetes Center. This event showcased a tremendous commitment from the community to support diabetes research and the organization’s initiatives.

Investment in Diabetes Research and Support

The funds raised during this gala will primarily be directed towards critical research efforts, alongside initiatives aimed at diabetes outreach and prevention. An important part of this financial support also goes to sponsor children for Camp Blue Hawk, an esteemed residential summer camp designed specifically for youth aged 9 to 17 living with Type 1 diabetes. Such efforts not only provide recreational opportunities for children but also enhance their understanding and management of diabetes.

Celebrating Contributions of Distinguished Guests

Emceeing the event was Robin Marsh, a renowned Emmy Award-winning journalist associated with KWTV News 9 in Oklahoma City. The evening was further enriched by a captivating performance from eight-time Grammy Award winner Carrie Underwood, showcasing the blend of celebration and philanthropy throughout the night.

Recognition of Exceptional Research

A highlight of the evening was the awarding of the prestigious Harold Hamm International Prize for Biomedical Research in Diabetes to Professor Dr. Anette-Gabriele Ziegler, an esteemed director at the Institute of Diabetes Research. This prize is granted to distinguish significant contributions in diabetes research aimed at creating advances for Type 1 or Type 2 diabetes patients.

A Legacy of Impact and Philanthropy

Dr. Ziegler's impactful research aims to provide hope through her groundbreaking projects, including numerous long-term studies and clinical trials that contribute significantly to public health advancements. Her work has played a pivotal role in the approval of teplizumab, the first drug capable of delaying the onset of Type 1 diabetes in individuals at risk. This accomplishment emphasizes the importance of ongoing research and discovery in the pursuit of better health solutions.

Community Recognition and Award

Honoring Harold Hamm's extraordinary contributions, the University of Oklahoma also presented him with the inaugural Crystal Seed Sower Award. This award recognizes substantial philanthropic support that influences and shapes institutions positively. Thanks to Hamm's generosity, the OU Health Harold Hamm Diabetes Center has evolved into a beacon of excellence in diabetes research.

Future Outlook for Diabetes Research

The continuous growth of funding from the National Institutes of Health illustrates the center's enhanced research capacity. Under Hamm's guidance, the center’s research funding surged impressively from $5 million to $33 million, enabling more extensive and innovative research studies.

Commitment to Community Health

OU President Joseph Harroz Jr. acknowledged the tremendous contributions looking forward to address the ongoing diabetes crisis, emphasizing Hamm's enduring impact on the health and well-being of the community. His philanthropy not only reflects compassion but underscores a profound belief in the transformative power of scientific research.

About the University of Oklahoma

Established in 1890, the University of Oklahoma stands as a public research university with extensive campuses dedicated to serving the educational, cultural, and health care needs of students and the broader community. The OU Health Campus, one of the leading academic health centers in the nation, comprises several health profession colleges and caters to a diverse population, preparing the next generation of health professionals.

Frequently Asked Questions

What was the purpose of the Connect+Cure Gala?

The Connect+Cure Gala aimed to raise funds to support diabetes research and outreach programs at the University of Oklahoma Health Harold Hamm Diabetes Center.

Who was awarded the Harold Hamm International Prize?

Professor Dr. Anette-Gabriele Ziegler received the Harold Hamm International Prize for Biomedical Research in Diabetes for her remarkable contributions to the field.

What types of programs will benefit from the raised funds?

The majority of the funds will support diabetes research and outreach programs, including sponsoring participants for Camp Blue Hawk.

How much funding was raised at the gala?

More than $4.7 million was raised during the Connect+Cure Gala to enhance diabetes research and prevention initiatives.

Why is Harold Hamm significant to the diabetes community?

Harold Hamm's philanthropic efforts have significantly advanced diabetes research, making the OU Health Harold Hamm Diabetes Center a national leader in the field.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 169

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 133

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 563

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 555

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 404

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 207

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 164

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 315

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 83

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 61

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking Interoperability: The Free Partner Edition by interop.io

Updated Category News Views 230

Unlocking New Potential in Fintech with Free Edition interop.io, known as a frontrunner in desktop interoperability, is set to revolutionize the way fintech companies operate with the introduction of a cost-free edition of their software suite, named io.Connect. This new initiative aims to provide fintechs, regardless of their size or stage, with the opportunity to adopt...

Continue Reading
Massage Envy Celebrates Scholarship Winners and Their Future

Updated Category News Views 164

Massage Envy Celebrates Scholarship Winners Eight outstanding individuals have been recognized as winners of the Massage Envy National Scholarship Sweepstakes, each receiving a $2,500 scholarship to support their journey into the massage therapy profession. This initiative demonstrates Massage Envy's commitment to fostering the next generation of talented massage...

Continue Reading
Paul Mueller Company Updates Investors on Dividend Plans

Updated Category News Views 397

Paul Mueller Company Declares Cash Dividend Paul Mueller Company (OTC: MUEL) has some exciting news for its investors. The company has recently announced that its Board of Directors has declared a cash dividend of $0.30 per share on its outstanding common stock. This dividend reflects the company’s ongoing commitment to providing value to its shareholders. Details of...

Continue Reading
Photocure Enhances Leadership with Jane Healy as GM EMEA

Updated Category News Views 360

Photocure Welcomes Jane Healy as Vice President and General Manager EMEA Photocure ASA (OSE: PHO), known as the Bladder Cancer Company, has made a significant move by appointing Jane Healy as the new Vice President and General Manager for the EMEA region. This strategic decision underscores Photocure's commitment to enhancing its leadership in the uro-oncology sector....

Continue Reading
TDS Hits Bumps but Keeps Shareholders Happy

Updated Category News Views 48

High Hopes and Hard Hits: TDS in 2026 Listen up, folks. Telephone and Data Systems, Inc. (NYSE: TDS) just popped the hood on their third quarter earnings, and it's a mixed bag with plenty to chew over. Operating revenues are slightly down from last year, but management's got some tricks up their sleeves. CEO Walter Carlson is trumpeting their expanded fiber service...

Continue Reading